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Abstract
Background: Functional mitral regurgitation (MR) is a common finding in dilated cardio-
myopathy. Left ventricular (LV) reverse remodeling with LV size reduction and improvement in 
LV function is a well recognized phenomenon. We aimed to evaluate the impact of LV remod-
eling on the mechanism leading to functional MR.
Methods: Among 188 patients with non-ischemic dilated cardiomyopathy, 10 patients sig-
nificantly improved their LV function, reduced LV size and MR severity during follow-up 
(RRMR). A comparison was made between their baseline and follow-up echocardiographic 
examinations and to a matched-control group of patients who did not improve (no RRMR). LV 
and left atrium (LA) dimensions and volumes, LV mass (LVM), LV ejection fraction (LVEF) 
(Simpsons), sphericity index (SI), mitral valve tenting area (TA) coaptation distance (CD), 
effective regurgitant orifice (ERO), and regurgitant volume were calculated. Multivariable 
analysis was performed in order to evaluate which echocardiographic parameters related to 
MR improvement in reverse remodeling.
Results: LV and LA dimensions and volumes, LVM, SI, TA, CD, ERO and right ventricle, in 
the RRMR group significantly decreased at follow-up (p < 0.04 for all). When compared to no 
RRMR, despite a similar ERO (0.2 ± 0.05 vs. 0.2 ± 0.08, p = 0.13) and a larger regurgitant 
volume (38 ± 9 vs. 29 ± 8 mL, p = 0.05) and despite similar clinical characteristics and 
medical treatment we found significantly higher LVEF, smaller LV dimensions and volumes, 
smaller LVM and SI in the RRMR group (p < 0.05 for all). On multivariable analysis the SI 
was the sole predictor of RRMR (p = 0.04, OR = 0.76, CI 0.58–0.99).
Conclusions: Reverse remodeling characterized by improvement in LV function, reduction in 
LV size and an associated reduction in MR severity is related to LV SI at baseline. (Cardiol J  
2015; 22, 4: 391–396)
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Introduction
Dilated cardiomyopathy (DCM) is a syndrome 
characterized by cardiac enlargement and impaired 
systolic function of one or both ventricles [1, 2]. 
Functional mitral regurgitation (MR) is a com-
mon finding in patients with DCM resulting from 
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increased sphericity of ventricular geometry and 
apico-lateral displacement of the papillary muscles 
[3, 4]. MR exacerbates the volume overload of 
the already dilated left ventricle (LV), leading to 
progressive ventricular and annular dilation, heart 
failure deterioration and predicts a poor survival 
[5–7]. Reverse remodeling, a well recognized phe-
nomenon characterized by a decrease in LV size 
in association with normalization of LV shape 
and improvement in LV function, occurs in about 
a third of DCM patients under contemporary treat-
ment [8]. This process is sometimes associated 
with a variable reduction in the severity of MR. In 
the current study we evaluated the mechanisms 
associated with improvement of MR in patients 




Serial echo-Doppler studies were performed 
every 6–24 months or as clinically indicated. LV 
and left atrial (LA) dimensions were measured 
according to the American Society of Echocardi-
ography guidelines for chamber quantification [9] 
Right ventricular (RV) fractional area change was 
calculated from the apical 4-chamber view. LV 
end-systolic and end-diastolic volumes (LVESV, 
LVEDV) and LV ejection fraction (LVEF) function 
were measured according to the Simpsons’ method 
of discs averaging 3 consecutive beats. LA volume 
was measured using the Simpson’s method from 
the 4 chamber apical view, indexed to body surface 
area (BSA), LA volume index (LAVi). Care was 
taken to exclude the pulmonary veins from the 
LA tracing. LV mass (LVM) was measured accord-
ing to the Devereux formula and indexed to BSA 
(LVMi). In order to assess changes in LV shape, the 
sphericity index (SI) was calculated as the short 
to long axis ratio in the 4 chamber view. Tenting 
area was defined as the area enclosed between 
the annular plane and the mitral leaflets from the 
parasternal long axis view at mid-systole. Coapta-
tion distance was defined as the distance between 
the annular plane and the coaptation point at mid 
systole in the 4 chamber apical view. The effective 
regurgitant orifice and the regurgitant volume were 
calculated according to the PISA method and the 
MR was graded on 4 point scale, minimal or none/ 
/minimal — 0, mild — 1, moderate — 2, severe 
— 3. Improvement in MR ≥ 1 grade was defined 
as significant. Reverse remodeling of the LV was 
defined as an increase in LVEF by at least 10% units 
concomitant with a decrease in the LV end-diastolic 
dimension (LVEDD) index by at least 10% relative 
to the baseline measurement.
Patient population
The Sheba Heart Failure clinic is a tertiary 
center taking care of heart failure patients. As we 
previously reported [10], our clinical database in-
cludes 233 patients with DCM examined between 
2004 and 2008 with subsequent follow-up. One 
hundred and eighty-eight patients with mean age 
58 ± 16 years (range 11–93 years), 115 (61%) male, 
LVEF 28 ± 9% (range 10–48%), LVEDD 60 ± 8 mm 
(range 42–88 mm), LV end-systolic dimension 
(LVESD) 47 ± 9 mm (range 28–82 mm) had 
a complete follow-up (mean follow-up time 82 ± 35 
months). Seventy-three patients were hyperten-
sive and 42 diabetic. The etiology was familial in 
37, post-chemotherapy in 18, pregnancy-related in 
19 and probably tachycardia-induced in 25 patients. 
Nineteen patients had conduction system disease 
and 11 patients declared about previous substance 
abuse. The etiology was idiopathic in the remain-
ing patients. Patients with associated significant 
coronary artery disease (ruled out by coronary 
angiography or radionuclide scan) and valvular 
heart disease were not included in the database. 
Ninety-three patients did not improve their LVEF 
by ≥ 10% and did not decrease their LVEDD index 
by ≥ 10% during follow-up, 37 patients improved 
their LVEF without decreasing their LVEDD, 
8 patients reduced their LVEDD without improving 
their LVEF while 50 patients improved their LVEF 
and reduced LVEDD index during the follow-up. 
The prevalence of ≥ grade 2 MR was similar among 
the groups (p = 0.1), while improvement in the 
severity of MR at follow-up was significantly better 
in the patients who improved LVEF and reduced 
their LVEDD index (p = 0.008, Fig. 1).
Twelve of the 50 patients who improved 
LVEF and reduced their LVEDD index had at 
least moderate MR at baseline and significantly 
reduced their MR severity by ≥ 1 grade at long-
term follow-up. Ten of them had good quality 
follow-up echocardiograms available for evaluation 
(RRMR group). Their baseline echocardiographic 
examinations were compared to their follow-up 
echo examinations (after improvement) look-
ing for the morphologic changes related to the 
reduction in MR severity. Thereafter, their first 
echo examinations were compared to the first 
echo examinations of a matched control group 
of patients with similar LV dysfunction and MR 
severity at baseline who did not reverse remodel 
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their LV and did not improve their MR during the 
follow-up (no RRMR group).
The study protocol was approved by our in-
stitutional ethic committee for human research.
Statistical methods
Baseline and follow-up echocardiographic 
values were compared using the paired sample 
t-test or the Wilcox signed-rank test, as appropri-
ate. The echocardiographic characteristics of the 
patients who improved LV function and reduced 
MR severity (RRMR) were compared to matched 
patients that did not improve LV function or reduce 
MR severity (no RRMR). Comparison of categori-
cal variables was performed with χ2 analysis and 
comparison of continuous variables was performed 
with the student’s t-test for variables with normal 
distribution and by Kruskal-Wallis for those that 
violated the normality assumption.
In order to evaluate the independent association 
of baseline echocardiographic parameters with the 
probability of RRMR we selected co-variates that 
were associated with RRMR in a univariable level, 
at a significance level of ≤ 0.01. The univariable 
association of each echocardiographic parameter, 
LA dimesion (mm), LA area (cm2), LAVi (mL/m2), 
RV-fractional area change (%), LVEDD (mm), 
LVESD (mm), LVEDV (cm3), LVESV (cm3), LVEF 
(%), LVM (g), LVMi (g/m2), effective regurgitant 
orifice (mm2), regurgitant volume (mL), SI, coap-
tation distance (cm), tenting area (cm2), with the 
RRMR outcome, was separately assessed using 
a binary logistic regression model. Co-variates 
were introduced using the enter method, and the 
adjusted odds ratio are presented with their 95% 
confidence interval (CI).
All p values were 2-sided, and a p value ≤ 0.05 
was considered significant. The statistical software 
used was SPSS version 20 (IBM Inc.).
Results
The baseline echocardiographic findings of 
the RRMR patients were compared with their 
findings after the follow-up. Effective regurgitant 
orifice decreased from 0.2 ± 0.05 to 0.01 ± 0.03, 
p < 0.0001. The regurgitant volume was 38 ± 9 mL 
at admission and was immeasurable (due to in-
significant MR) in most patients at follow-up. 
The RV area changes significantly increased from 
45 ± 5% at baseline to 52 ± 9% at follow-up (p = 
= 0.03). LA and LV dimensions, LVM, LVMi (LVM/ 
/body surface area), LVESV and LVEDV, LAVi, SI, 
mitral valve tenting area and coaptation distance 
were all significantly smaller at follow-up after 
reverse remodeling (Table 1). In Table 2, the 
baseline clinical characteristics of the 10 patients 
with reverse remodeling (RRMR) are compared 
with 10 matched controls who did not reverse 
remodel at follow-up (no RRMR). No differences 
were found between the groups. In Table 3, the 
baseline echocardiographic characteristics of the 
matched groups are compared. The effective re-
gurgitant orifice was similar in both groups (0.2 ± 
± 0.05 and 0.2 ± 0.08, p = 0.13) respectively, while 
the regurgitant volume was significantly higher 
in the RRMR group than in the no RRMR group 
(38 ± 9 mL vs. 29 ± 8 mL, p = 0.05). When com-
pared to the no RRMR group baseline LA dimen-
sions, LAVi, LV dimensions, LVESV and LVEDV, 
LVM, LVMi and SI were all significantly smaller in 
the group who reverse remodeled at follow-up. On 
univariable analysis baseline LAVi, LVESV and SI 
where associated with RRMR (p < 0.01 for each). 
On multivariable analysis SI remained as the sole 
predictor of RRMR (p = 0.04, CI 0.58–0.99).
Figure 1. Prevalence of improvement in the severity of 
mitral regurgitation (MR) according to the pattern of left 
ventricular conformational changes at follow-up. There 
was no difference in the prevalence of significant MR 
among the groups (p = 0.1) but improvement in MR 
severity was more common in patients with reverse 
remodeling (p = 0.008); LVEF — left ventricular ejec-
tion fraction; LVEDD — left ventricular end-diastolic 
dimension.
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Discussion
The term DCM refers to a large group of 
heterogeneous myocardial disorders that are 
characterized by ventricular dilation and depressed 
myocardial contraction in the absence of abnormal 
loading conditions [1, 2]. Some DCM patients have 
a relatively benign clinical course and spontaneous-
ly improve symptoms and partially or completely 
recover their LV function [8]. Functional MR is 
a frequent finding in patients with DCM and its 
severity is associated with prognosis [5–7]. The 
Table 1. Baseline and follow-up echocardiographic dimensions in patients who reverse remodeled and 
reduced mitral regurgitation (n = 10).
Baseline Follow-up P
Left atrial dimension [mm] 42 ± 4 37 ± 6 0.02
Left atrial area [cm2] 24 ± 4 21 ± 6 0.3
LAVi [mL/m2] 35 ± 6 27 ± 9 0.04
RV-FAC [%] 45 ± 5 52 ± 9 0.03
LVEDD [mm] 57 ± 2 48 ± 5 > 0.001
LVESD [mm] 45 ± 6 31 ± 4 > 0.001
LVEDV [cm3] 135 ± 37 94 ± 24 0.006
LVESV [cm3] 98 ± 34 48 ± 13 > 0.001
LVEF [%] 28 ± 10 48 ± 10 > 0.001
LVM [g] 231 ± 38 187 ± 49 0.02
LVM index [g/m2] 124 ± 15 100 ± 22 0.02
ERO [mm2] 0.2 ± 0.05 0.01 ± 0.03 < 0.0001
Regurgitant volume [mL] 38 ± 9 Not measurable < 0.0001
Sphericity index 0.56 ± 0.07 0.5 ± 0.07 0.04
Coaptation distance [cm] 0.79 ± 0.23 0.48 ± 0.14 > 0.001
Tenting area [cm2] 2.53 ± 0.52 1.48 ± 0.4 0.003
LAVi — left atrial volume/body surface area; RV-FAC — right ventricular fractional area change, LVEDD — left ventricular end-diastolic diam-
eter; LVESD — left ventricular end-systolic diameter; LVEDV — left ventricular end-diastolic volume, LVESV — left ventricular end-systolic 
volume; LVEF — left ventricular ejection fraction; LVM — left ventricular mass; ERO — effective regurgitant orifice
Table 2. Baseline clinical characteristics of the matched groups.
PNo RRMRRRMR
1010No. of patients
0.960 ± 2061 ± 17Age [years]
0.66 (60%)5 (50%)Male sex
0.727 ± 826 ± 3BMI [kg/m2]




0.22 (20%)5 (50%)Renal failure
0.087 (70%)3 (30%)Mineralocorticoid antagonist
0.5569 (90%)8 (80%)ACEI/ARB
0.15110 (100%)8 (80%)Beta-blocker
RRMR — patients who improved left ventricular function, reduced left ventricular end-diastolic dimension (LVEDD) and reduced mitral regur-
gitation severity at follow-up;  No RRMR — patients who did not improve left ventricular function, did not reduce LVEDD and did not reduce 
mitral regurgitation severity at follow-up; BMI — body mass index; BSA — body surface area; CMP — cardiomyopathy; ACEI — angiotensin 
converting enzyme inhibitors; ARB — angiotensin receptor blocker
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pathophysiology of functional MR has been widely 
investigated. Functional MR develops because of 
a combination of mitral leaflet tethering second-
ary to LV dilatation/deformation with papillary 
displacement/discoordination, annular dilatation/ 
/dysfunction, insufficient LV-generated closing 
forces attributable to reduction of LV contractility, and 
global LV/papillary muscle dyssynchrony [11, 12]. 
Tethering of the mitral leaflets is the principal 
lesion of functional MR and results in restriction 
of systolic leaflet motion functional MR does not 
typically occur in global LV dysfunction without 
tethering. However, once tethering occurs, leaf-
let closure is further impaired by LV dysfunction 
because of decreased force opposing tethering 
[13–16]. The key event in the pathogenesis of func-
tional MR is the distortion of normal LV geometry 
(LV remodeling) with subsequent apical and lateral 
displacement of papillary muscles, which, in turn, 
draws the chordae tendineae away from the line 
of coaptation [14, 15]. In this study, a significant 
reduction in the severity of MR occurred in 24% of 
the patients who underwent reverse remodeling, 
i.e. improved their LV function and concomitantly 
decreased their LV diastolic dimensions. Disap-
pearance of MR was much less prevalent in patients 
who improved only one of these variables (Fig. 1). 
Our findings suggest that the improvement in MR 
in patients with DCM who reverse remodeled 
is related to the reduction of LV dimensions and 
changes in LV shape but is determined by the LV 
shape at baseline. This reduction in LVESV and 
LVEEV, as well as the reduction in the SI translate 
into a reduction in the coaptation distance and in 
tenting area with a consequent reduction in the 
severity of MR depending on the SI at baseline so 
that the higher the SI at baseline the worse the 
chances are of reverse remodeling. In this study, 
per each 0.01 increment in the baseline SI the odds 
ratio for reverse remodeling was reduced by 24%. 
The practical implication is that mitral valve appa-
ratus acts as a “marionette” of LV conformational 
changes [17], but the chance of reverse remodeling 
is related to the LV conformational changes at base-
line (Table 3). Importantly, the SI was only mildly 
affected by the process of RRMR (Table 1) and 
thus emerged as a fundamental property of the LV 
affecting prognosis. Actually, an ellipsoid shape is 
vital for optimal LV function. In pathological disease 
states such as DCMs there is a loss of the obliquity 
of the cardiac myofibers leading to a more globular 
LV shape which initiate the cascade of heart failure 
[18]. The comparison of a group of patients with 
reverse remodeling and significant MR reduction 
to a group of patients who did not reverse remodel 
showed similar clinical characteristics at baseline. 
Patients who did not reduce their LV dimensions or 
recover their LV shape did not improve their MR. 
Table 3. Baseline echocardiographic characteristics of the matched groups.
RRMR (n = 10) No RRMR (n = 10) P
Left atrial dimension [mm] 42 ± 4 49 ± 5 0.005
Left atrial area [cm2] 24 ± 4 30 ± 7 0.025
LAVi [mL/m2] 35 ± 6 49 ± 16 0.03
RV-FAC [%] 45 ± 5 42 ± 10 0.4
LVEDD [mm] 57 ± 2 67 ± 9 0.002
LVESD [mm] 45 ± 6 58 ± 9 0.002
LVEDV [cm3] 135 ± 37 188 ± 61 0.03
LVESV [cm3] 98 ± 34 150 ± 55 0.02
LVEF [%] 28 ± 10 21 ± 4 0.05
LVM [g] 231 ± 38 318 ± 121 0.04
LVM index [g/m2] 124 ± 15 177 ± 78 0.05
ERO [mm2] 0.2 ± 0.05 0.2 ± 0.08 0.13
Regurgitant volume [mL] 38 ± 9 29 ± 8 0.05
Sphericity index 0.56 ± 0.07 0.66 ± 0.05 0.003
Coaptation distance [cm] 0.79 ± 0.23 0.95 ± 0.38 0.2
Tenting area [cm2] 2.53 ± 0.52 2.14 ± 0.48 0.1
Abbreviations as in Tables 1 and 2.
www.cardiologyjournal.org 395
Rafael Kuperstein et al., Reverse remodeling and improvement in mitral regurgitation
Importantly, similar changes in LV geometry and 
LV contraction have been described and found to 
be associated with improvement in functional MR 
severity after cardiac resynchronization therapy 
[19–22]. It remains to be determined how the 
SI and the capacity to revert MR are related to 
epidemiological features such as disease duration 
and etiology.
Limitations of the study
The current study population was enrolled 
in a tertiary referral center for cardiomyopathies 
and heart failure, thus imposing a selection bias 
with respect to the characteristics of DCM in the 
general population. It is a small observational 
study and prospective echo-Doppler follow-up 
was not available in some patients. The measure-
ments were performed by a single operator (R.K.) 
who was not blinded to the results of the baseline 
echocardiographic studies. The baseline effective 
regurgitant orifice was similar between the RRMR 
and the no RRMR group but the regurgitant volume 
was not. This can be explained by the fact that 
values defining MR severity in individual patients 
depend on multiple factors including LVEDV, LVEF 
and the pressure gradient between LA and LV [23]. 
Finally, the ideal control group for this study would 
comprise patients who reverse remodeled and did 
not reduce the severity of their MR. However, 
this comparison was not possible due to the small 
number of participants.
Conclusions
Reverse remodeling is a common finding in 
DCM under contemporary therapy involving ~ 1/4 
of patients with established disease. Reduction in 
the severity of functional MR is quite prevalent in 
patients with DCM who present with significant 
MR and reverse remodel during follow-up. In 
patients with less distorted LV shape at baseline 
a further reduction in LV dimension in association 
with changes in LV shape and function translate 
into less valvular tethering, better leaflet coapta-
tion and improvement in functional MR.
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